Merck KGaA (MRCG)

Real-time derived
Currency in EUR
Disclaimer
142.00
-2.45(-1.70%)
Closed
Day's Range
141.05145.05
52 wk Range
135.00202.80
Prev. Close
142
Open
144.7
Day's Range
141.05-145.05
52 wk Range
135-202.8
Volume
523,395
Average Volume (3m)
348,653
1-Year Change
-21.11%
Shares Outstanding
434,777,878
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
186.62
Upside +31.42%

People Also Watch

52.74
SHLG
+1.03%
23.74
MT
+0.70%
180.500
DB1Gn
+1.23%
28.530
FREG
+0.04%
19.740
ELE
+0.36%
How do you feel today about MRCG?
Vote to see community's results!
or

Merck KGaA Company Profile

Merck KGaA operates as a science and technology company in Germany. The company’s Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry kits and instruments for pharma and biotech, industrial and testing, academics and government, and diagnostic sectors. Its Healthcare segment designs and develops medicines and intelligent devices for treatment of various therapeutics, such as oncology, neurology and immunology, endocrinology, and general medicines. The company’s Electronic segment provides semiconductor solutions, such as semiconductor materials, delivery systems and services, and intermolecular services for semiconductor and polymer removal chemistries applications; and display solutions comprising liquid crystals, OLED and quantum materials, reactive mesogens, photoresist materials, smart antenna, and dynamic liquid crystal glazing products, as well as offers liviFlex, a flexible platform, which offers a range of display materials. This segment also provides surface solution, such as cosmetics, effect pigments, and functional solutions; architecture solutions, including switchable windows; and automotive solutions. In addition, it has strategic alliances with Pfizer Inc. and GlaxoSmihKline plc to develop and commercialize active ingredients in immune-oncology; in-licensing agreement with Debiopharm International SA for developing drug candidates for the treatment of head and neck cancer; and out-licensing agreement with MoonLake Immunotherapeutics AG for developing a drug candidate for the treatment of inflammatory diseases. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Employees
63712
Market
Germany